相关实验视频
Updated: May 31, 2026

09:03
The CYP2D6 Animal Model: How to Induce Autoimmune Hepatitis in Mice
Published on: February 3, 2012
19.1K
在自身免疫性肝炎中对生物疗法的评估:基于病例的系统性审查
Haifa Eldew1, Jonathan Soldera2
1Consultant in Acute Internal Medicine with Specialist Interest in Hepatology, Princess Royal University Hospital, Kings College Hospital Foundation Trust, Orpington Kent BR6 8ND, United Kingdom.
World journal of gastrointestinal pathophysiology
|March 24, 2025
概括
像贝利马布和利图西马布这样的生物疗法对自身免疫性肝炎 (AIH) 患者有希望,这些患者对标准治疗有抗性. 一些抗瘤亡因子 (TNF) 药物可以诱导AIH,需要仔细监测.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 自体免疫性肝炎 (AIH) 通常使用免疫调节剂和类固醇来管理.
- 一部分AIH患者表现出对标准治疗的折射性,需要使用替代治疗策略.
- 生物疗法正在成为耐火AIH病例的潜在选择.
研究的目的:
- 评估生物疗法在自身免疫性肝炎 (AIH) 的疗效和安全性.
- 专注于那些对传统治疗无反应的AIH患者.
- 评估结果,包括血清学标志物和组织学缓解.
主要方法:
- 根据PRISMA协议进行了系统审查.
- 通过对MEDLINE,EMBASE和Cochrane图书馆数据库进行全面搜索来确定研究.
- 用生物药物治疗的成年AIH患者的数据使用叙事合成进行了分析.
主要成果:
- 在两项研究中,在8名AIH患者中,贝利马布在5名患者中显示出了良好的反应.
- 利图西马布的疗效很高,在6项研究中,45名患者中有41人经历了显著的改善.
- 抗瘤坏死因子 (TNF) 疗法与20例AIH诱导有关,在药物停用后得到缓解.
结论:
- 贝利马布和利图西马布代表了耐火AIH的有希望的替代品,改善了临床和肝功能标志物.
- 个性化治疗方法至关重要,因为患者对不同生物制剂的反应是可变的.
- 对抗TNF疗法诱导的AIH进行警监测至关重要.
相关概念视频
Autoimmune Disorders
Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune system...
Concept and Mechanism of Autoimmune Diseases
The immune system...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Hepatitis
Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Viral Hepatitis I: Introduction
Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...

